News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
726,932 Results
Type
Article (41447)
Company Profile (265)
Press Release (685206)
Multimedia
Podcasts (85)
Webinars (20)
Section
Business (204819)
Career Advice (2028)
Deals (35559)
Drug Delivery (121)
Drug Development (81506)
Employer Resources (173)
FDA (16471)
Job Trends (14973)
News (346744)
Policy (32752)
Tag
2027 BioCapital Elite (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2596)
Accelerated approval (42)
Adcomms (25)
Allergies (160)
Alliances (49606)
ALS (192)
Alzheimer's disease (1745)
Antibody-drug conjugate (ADC) (366)
Approvals (16788)
Artificial intelligence (595)
Autoimmune disease (222)
Automation (50)
Bankruptcy (362)
Best Places to Work (11641)
BIOSECURE Act (20)
Biosimilars (201)
Biotechnology (175)
Bladder cancer (177)
Brain cancer (63)
Breast cancer (686)
Cancer (5303)
Cardiovascular disease (442)
Career advice (1717)
Career pathing (39)
CAR-T (299)
CDC (53)
Celiac Disease (2)
Cell therapy (798)
Cervical cancer (41)
Clinical research (70252)
Collaboration (1890)
Company closure (4)
Compensation (1270)
Complete response letters (69)
COVID-19 (2727)
CRISPR (98)
C-suite (974)
Cystic fibrosis (148)
Data (7048)
Decentralized trials (3)
Denatured (26)
Depression (154)
Dermatology (57)
Diabetes (549)
Diagnostics (6825)
Digital health (53)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (293)
Drug pricing (194)
Drug shortages (29)
Duchenne muscular dystrophy (265)
Earnings (91060)
Editorial (60)
Employer branding (21)
Employer resources (152)
Events (118405)
Executive appointments (1030)
FDA (19885)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (29)
Funding (1614)
Gene editing (210)
Generative AI (52)
Gene therapy (651)
GLP-1 (1014)
Government (4693)
Grass and pollen (6)
Guidances (396)
Healthcare (18933)
HIV (73)
Huntington's disease (53)
IgA nephropathy (91)
Immunology and inflammation (271)
Immuno-oncology (80)
Indications (157)
Infectious disease (3039)
Inflammatory bowel disease (201)
Inflation Reduction Act (14)
Influenza (128)
Intellectual property (273)
Interviews (316)
IPO (16652)
IRA (50)
Job creations (3649)
Job search strategy (1430)
JPM (58)
Kidney cancer (18)
Labor market (92)
Layoffs (553)
Leadership (34)
Legal (7952)
Liver cancer (98)
Longevity (28)
Lung cancer (713)
Lymphoma (406)
Machine learning (52)
Management (59)
Manufacturing (917)
MASH (176)
Medical device (13861)
Medtech (13938)
Mergers & acquisitions (20064)
Metabolic disorders (1406)
mRNA (173)
Multiple sclerosis (172)
NASH (17)
Neurodegenerative disease (382)
Neuropsychiatric disorders (97)
Neuroscience (3137)
Neurotech (1)
NextGen: Class of 2026 (6529)
Non-profit (4532)
Now hiring (73)
Obesity (661)
Opinion (274)
Ovarian cancer (185)
Pain (229)
Pancreatic cancer (253)
Parkinson's disease (338)
Partnered (33)
Patents (552)
Patient recruitment (587)
Peanut (60)
People (59247)
Pharmaceutical (59)
Pharmacy benefit managers (32)
Phase 1 (21908)
Phase 2 (30933)
Phase 3 (23031)
Pipeline (7096)
Policy (302)
Postmarket research (2564)
Preclinical (9292)
Press Release (64)
Prostate cancer (274)
Psychedelics (49)
Radiopharmaceuticals (302)
Rare diseases (989)
Real estate (5961)
Recruiting (70)
Regulatory (24962)
Reports (54)
Research institute (2418)
Resumes & cover letters (353)
Rett syndrome (32)
RNA editing (17)
RSV (85)
Schizophrenia (163)
Series A (267)
Series B (201)
Service/supplier (11)
Sickle cell disease (106)
Special edition (22)
Spinal muscular atrophy (164)
Sponsored (45)
Startups (3629)
State (2)
Stomach cancer (18)
Supply chain (117)
Tariffs (85)
The Weekly (57)
Vaccines (1054)
Venture capital (98)
Weight loss (420)
Women's health (109)
Worklife (19)
Date
Last 7 days (636)
Last 30 days (2447)
Last 365 days (29894)
2026 (7985)
2025 (30199)
2024 (35239)
2023 (40094)
2022 (51209)
2021 (55738)
2020 (54105)
2019 (46569)
2018 (35035)
2017 (32143)
2016 (31524)
2015 (37599)
2014 (31354)
2013 (26404)
2012 (28600)
2011 (29297)
2010 (27357)
Location
Africa (739)
Alabama (90)
Alaska (7)
Arizona (331)
Arkansas (13)
Asia (39504)
Australia (6459)
California (12256)
Canada (3506)
China (1227)
Colorado (522)
Connecticut (520)
Delaware (366)
Europe (85336)
Florida (1847)
Georgia (394)
Hawaii (3)
Idaho (62)
Illinois (955)
India (80)
Indiana (558)
Iowa (22)
Japan (485)
Kansas (129)
Kentucky (44)
Louisiana (39)
Maine (73)
Maryland (1482)
Massachusetts (8756)
Michigan (346)
Minnesota (674)
Mississippi (6)
Missouri (138)
Montana (33)
Nebraska (29)
Nevada (135)
New Hampshire (82)
New Jersey (3271)
New Mexico (28)
New York (3234)
North Carolina (1552)
North Dakota (8)
Northern California (6058)
Ohio (365)
Oklahoma (22)
Oregon (41)
Pennsylvania (2481)
Puerto Rico (26)
Rhode Island (50)
South America (1113)
South Carolina (76)
South Dakota (1)
Southern California (4818)
Tennessee (199)
Texas (1924)
United States (43404)
Utah (368)
Vermont (1)
Virginia (291)
Washington D.C. (80)
Washington State (980)
West Virginia (4)
Wisconsin (118)
Wyoming (2)
726,932 Results for "renovo neural inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update
March 30, 2026
·
18 min read
Press Releases
Neural Therapeutics Strengthens IP Portfolio With a Patent Application
Treatment of Major DSM-5 Disorders, Including Addiction, Depression and Anxiety, With Sub-Hallucinogenic Mescaline Doses Extraction Technology Delivering Higher Yields and Greater Purity Frankfurt Stock Exchange Ticker Symbol Changed to “HANF” Extension of LOI with CWE European Holdings (dba Hanf.com)
April 14, 2025
·
7 min read
Press Releases
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment
March 26, 2026
·
9 min read
Press Releases
Neural Therapeutics Announces RSU and Options Grant
May 13, 2025
·
5 min read
Press Releases
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement
March 23, 2026
·
12 min read
Neural Therapeutics Receives Conditional Approval to Listing on the CSE and Announces Concurrent Financing
Toronto, Ontario--(Newsfile Corp. - May 8, 2024) - Neural Therapeutics Inc. (“Neural” or the “Company”), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs for mental ailments related to substance use disorders...
May 8, 2024
·
8 min read
Press Releases
RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET
March 20, 2026
·
8 min read
Press Releases
RenovoRx Announces $10 Million at Market Private Placement
March 18, 2026
·
10 min read
Press Releases
Neural Announces Completion of the Acquisition of a 30.75% Interest in Hanf.com, a Profitable German CBD Retail Store Chain
August 13, 2025
·
12 min read
Press Releases
Neural Announces Approval of the Strategic Investment and Option Agreement by CWE Shareholders to Acquire up to 100% of CWE
July 22, 2025
·
5 min read
Previous
2 of 72,694
Next
